Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.70 |
| ▸ | PPARG | P37231 | 6/20 | 0.60 |
| ▸ | PPARA | Q07869 | 1/20 | 0.60 |
| ▸ | ATP4A | P20648 | 7/20 | 0.46 |
| ▸ | ATP4B | P51164 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178690 | 0.84 | PPARG (0.80) | PPARDPPARGPPARA | |
| SCHEMBL1847312 | 0.84 | PPARG (0.80) | PPARDPPARGPPARA | |
| SCHEMBL1847314 | 0.83 | PPARG (0.66) | PPARDPPARGPPARA | |
| SCHEMBL6801314 | 0.82 | PPARG (0.70) | PPARDPPARGATP4AATP4B | |
| SCHEMBL1845872 | 0.78 | PPARG (0.82) | PPARDPPARGPPARA | |
| SCHEMBL1845874 | 0.77 | PPARD (0.62) | PPARDPPARGPPARAATP4AATP4B | |
| SCHEMBL14583577 | 0.75 | PPARD (0.62) | PPARDPPARGPPARA | |
| SCHEMBL14583571 | 0.74 | PPARD (0.61) | PPARDPPARGPPARA | |
| SCHEMBL14583580 | 0.74 | PPARD (0.60) | PPARDPPARGPPARA | |
| SCHEMBL6805155 | 0.74 | PPARD (0.57) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686475-B2 | THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES | BEECHAM GROUP P.L.C. (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | disclosed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | disclosed |
| US-6288095-B1 | ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC | BEECHAM GROUP P.L.C. (GB) | 2001-09-11 | — | — | US | disclosed |
| EP-0306228-B1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1999-11-17 | — | — | EP | disclosed |
| US-5756525-A | USING A THIAZOLIDINEDIONE COMPOUND | BEECHAM GROUP PLC (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | PPARD 4/4885PPARG 16/4885PPARA 20/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | PPARD 2170/4885PPARG 715/4885PPARA 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.